MedTrace Logo

Biomarker Establishment for Superior Treatment of PTSD

NCT03343028 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 292

Last updated 2020-02-12

No results posted yet for this study

Summary

The purpose of Biomarker Establishment for Superior Treatment of PTSD is to accelerate research on the discovery of biological, neurological and neuroimaging markers for Post- Traumatic Stress Disorder (PTSD). The investigators hope to validate and extend the network efficiency and verbal memory biomarker for PTSD. The investigators hope to learn whether there are pretreatment biological factors that can predict response to therapy. They want to do this by understanding the brain network function, relating EEG to functional magnetic resonance imaging, and application of network analysis tool.

Conditions

Interventions

OTHER

Psychotherapy

Sponsors & Collaborators

Principal Investigators

  • Alan Schatzberg, MD · Stanford University

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-09-30
Completion
2019-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03343028 on ClinicalTrials.gov